Results 21 to 30 of about 4,435,862 (297)
Direct oral anticoagulants: first airbag
Медицинский совет, 2019 The safety profile of oral anticoagulants (DOACs) was confirmed in the large-scale studies, the increased risk of hemorrhagic events does still exist, which may be caused by the nature of the patient’s concomitant pathology, the resulting injury or the ...
A. N. Sokolova, A. I. Skripka
doaj +1 more source
PLoS ONE, 2020 BACKGROUND:Warfarin is an anticoagulant medication proven effective in the initial treatment and secondary prevention of venous thromboembolism. Anti-Xa direct oral anticoagulants are alternatives to warfarin; however there is limited data assessing ...
Thomas Hendriks +5 more
doaj +1 more source
Edoxaban: an update on the new oral direct factor Xa inhibitor. [PDF]
, 2014 Edoxaban is a once-daily oral anticoagulant that rapidly and selectively inhibits factor Xa in a concentration-dependent manner. This review describes the extensive clinical development program of edoxaban, including phase III studies in patients with ...
Camm, AJ +3 more
core +1 more source
Oral anticoagulants: Optimizing venous thromboembolism management
Journal of Applied Hematology, 2019 A decade ago, oral anticoagulants were limited to Vitamin K antagonists, i.e., warfarin. Since 2010, the US Food and Drug Administration has approved several non-Vitamin K oral anticoagulants: dabigatran is a direct thrombin inhibitor, while apixaban ...
Fahad A S. Aleidan
doaj +1 more source
Direct oral anticoagulant reversal: An update
Nursing, 2020 Abstract: The rise in direct oral anticoagulant (DOAC) use means nurses must understand the reversal of these agents in case of bleeding. Depending on bleed severity, as well as other criteria, pharmacologic reversal can be considered in place of supportive care alone. Knowledge of literature surrounding DOAC reversal is crucial.
Andrea, Hafer, Lindsay, McCann
openaire +3 more sources
Use of New Oral Anticoagulants/ Direct Oral Anticoagulants in Malignant Patients [PDF]
Cureus, 2020 Vitamin K antagonists are being used in the last five decades as an effective anticoagulant. However, for the past few years, new oral anticoagulants (NOACs) have been introduced as newer anticoagulant agents, which are gradually replacing the previously used vitamin K antagonist.
Khan, Yusra +4 more
openaire +2 more sources
Monaldi Archives for Chest Disease, 2020 The number of patients treated with direct oral anticoagulants is increasing worldwide. Although bleeding complications associated with direct oral anticoagulants are lower than those associated with vitamin K antagonists, the increased number of ...
Alessandro Cipriano +4 more
doaj +1 more source
JACC: Case Reports, 2020 Left ventricular (LV) thrombus in patients with reduced LV systolic function carries significant thromboembolic risk. Direct oral anticoagulants are an attractive alternative to warfarin for LV thrombus management.
Usman Ghani, MD +3 more
doaj +1 more source
Direct oral anticoagulants in treatment of cerebral venous thrombosis: a systematic review protocol
Systematic Reviews, 2019 Background and purpose Cerebral venous thrombosis causes disability from venous infarct and hemorrhage and potential mortality. Anticoagulation improves survival and disability outcomes, yet direct oral anticoagulants are currently not indicated in ...
Gauruv Bose +4 more
doaj +1 more source
Journal of Cardiovascular Development and Disease, 2023 Left ventricular thrombus is a known complication following acute myocardial infarction that can lead to systemic thromboembolism. To obviate the risk of thromboembolism, the patient needs anticoagulation in addition to dual antiplatelet therapy. However,
Akshyaya Pradhan +6 more
doaj +1 more source